Volume 1 ; Issue 1 ; in Month : Jan-Dec (2019) Article No : 102
Panas RM, Brewer A III, Goldenson R, et al.

Abstract

The etiology of irritable bowel syndrome (IBS) is still not well-understood even with recent advances in treatments for IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D). Irritable bowel syndrome is a multifaceted condition characterized by abdominal pain and altered bowel habits. Consequently, no single treatment sufficiently manages IBS in a majority of patients. One option for treatment of IBS is to use a combination of different drugs or an all-in-one combination drug to help treat multiple aspects of the syndrome. Combination drugs which affect the brain-gut connection as well as an anticholinergic mechanism are standard-of-care for the treatment of IBS. They represent viable alternatives to newly approved agents. Even though drugs such as a combination of belladonna alkaloids/phenobarbital or Donnatal®, are used safely and effectively to manage IBS, their history of clinical investigation and results are not well-recognized by the field of gastroenterology given the lack of recent studies. This review is meant to update the field on the breadth of studies conducted on this combination drug for IBS.

Full Text Attachment

Views : 413      Downloads : 39

RSS